These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17932987)

  • 1. Successful treatment of fistulizing Crohn's disease with certolizumab pegol.
    Danese S; Stefanelli T; Omodei P; Zatelli S; Bonifacio C; Balzarini L; Repici A; Malesci A
    Inflamm Bowel Dis; 2008 Feb; 14(2):292-3. PubMed ID: 17932987
    [No Abstract]   [Full Text] [Related]  

  • 2. [Compassionate use of certolizumab in Crohn's disease].
    Planas-Giner A; Salort-Llorca C; Garriga-Biosca R; Esteve-Comas M
    Farm Hosp; 2008; 32(2):127-9. PubMed ID: 18783714
    [No Abstract]   [Full Text] [Related]  

  • 3. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study.
    Sandborn WJ; Schreiber S; Hanauer SB; Colombel JF; Bloomfield R; Lichtenstein GR;
    Clin Gastroenterol Hepatol; 2010 Aug; 8(8):696-702.e1. PubMed ID: 20363366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.
    Schreiber S; Colombel JF; Bloomfield R; Nikolaus S; Schölmerich J; Panés J; Sandborn WJ;
    Am J Gastroenterol; 2010 Jul; 105(7):1574-82. PubMed ID: 20234346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab.
    Sandborn WJ; Abreu MT; D'Haens G; Colombel JF; Vermeire S; Mitchev K; Jamoul C; Fedorak RN; Spehlmann ME; Wolf DC; Lee S; Rutgeerts P
    Clin Gastroenterol Hepatol; 2010 Aug; 8(8):688-695.e2. PubMed ID: 20451663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TNF antibodies for Crohn's disease.
    Camilleri M
    N Engl J Med; 2007 Oct; 357(16):1662; author reply 1662. PubMed ID: 17942882
    [No Abstract]   [Full Text] [Related]  

  • 8. Certolizumab pegol in Crohn's disease.
    Patel VK; Ghosh S
    Drugs Today (Barc); 2008 Nov; 44(11):837-44. PubMed ID: 19180261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral lichen planus after certolizumab pegol treatment in a patient with Crohn's disease.
    Mocciaro F; Orlando A; Renna S; Rizzuto MR; Cottone M
    J Crohns Colitis; 2011 Apr; 5(2):173-4. PubMed ID: 21453892
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.
    Schoepfer AM; Vavricka SR; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Seibold F; Straumann A; Michetti P;
    Inflamm Bowel Dis; 2010 Jun; 16(6):933-8. PubMed ID: 20014021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal meningoencephalitis after certolizumab pegol treatment in a patient with Crohn's disease.
    Majumder S; Kumar A
    J Crohns Colitis; 2013 Feb; 7(1):e19. PubMed ID: 22742971
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study.
    Schreiber S; Lawrance IC; Thomsen OØ; Hanauer SB; Bloomfield R; Sandborn WJ
    Aliment Pharmacol Ther; 2011 Jan; 33(2):185-93. PubMed ID: 21083671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Certolizumab pegol (CDP870) for treatment of Crohn's disease.
    Sisson G; Harris A
    Gastroenterology; 2006 Jan; 130(1):285-6; author reply 286. PubMed ID: 16401499
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-TNF antibodies for Crohn's disease--in pursuit of the perfect clinical trial.
    Lewis JD
    N Engl J Med; 2007 Jul; 357(3):296-8. PubMed ID: 17634466
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.
    Feagan BG; Sandborn WJ; Wolf DC; Coteur G; Purcaru O; Brabant Y; Rutgeerts PJ
    Aliment Pharmacol Ther; 2011 Mar; 33(5):541-50. PubMed ID: 21223344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: long-term safety and efficacy of certolizumab pegol for Crohn's disease.
    Cesarini M; Danese S
    Aliment Pharmacol Ther; 2014 Nov; 40(10):1243. PubMed ID: 25303376
    [No Abstract]   [Full Text] [Related]  

  • 17. The classics in perspective.
    Panés J; Ghosh S
    Gut; 2007 Sep; 56(9):1184-6. PubMed ID: 17698863
    [No Abstract]   [Full Text] [Related]  

  • 18. [Certolizumab pegol--new possibilities in the treatment of Crohn's disease].
    Lazebnik LB; Kniazev OV
    Eksp Klin Gastroenterol; 2012; (3):100-5. PubMed ID: 22830233
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial: improved efficacy of biological maintenance therapy in "early" compared with "late" Crohn's disease: strike while the iron is hot with anti-TNF agents?
    Ananthakrishnan AN; Binion DG
    Am J Gastroenterol; 2010 Jul; 105(7):1583-5. PubMed ID: 20606661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Certolizumab use in pregnancy.
    Oussalah A; Bigard MA; Peyrin-Biroulet L
    Gut; 2009 Apr; 58(4):608. PubMed ID: 19299393
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.